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Abstract
Background: We report herein a case of fecal microbiota transplantation (FMT) used for severe Clostridium difficile
infection for a 65-year-old Lebanese man who underwent left ventricular assist device implantation. To the best of
our knowledge this is the first case report from Lebanon and the region presenting such technique.
Case presentation: The patient experienced diarrhea and rectal bleeding and was diagnosed of pseudomembranous
colitis (PMC). His condition failed to improve on maximal pharmacological therapy. Protocolectomy, an invasive
operation consisting in resection of the entire colon and rectum seemed to be the last resort before the patient
responded to FMT given through gastroscopy.
Conclusion: Despite the increasing experience with FMT for C. difficile infection, published evidence in severe related
cases from this region is very limited. Hence, we promote adjunctive FMT, an effective noninvasive method, to be
considered as a promising early treatment option in severe C. difficile infection.
Keywords: Severe Clostridium difficile1, Left ventricular assist device implantation2, Fecal microbiota transplantation3,
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Background
Clostridium difficile, a ubiquitous spore-forming Gram
positive anaerobic bacillus, is the leading cause of anti-
biotic associated colitis which is among the most com-
mon infections implicated in increased-stay, morbidity
and mortality of hospitalized patients [1, 2]. Inflamma-
tion, apoptosis and necrosis of intestinal cells are attrib-
uted to the disruption of the intestinal microbial
equilibrium, which opens the floor for C. difficile to
colonize and produce potent enterotoxins and cytotoxins
[3]. Over the past few years, there has been an increas-
ing emergence of the hypervirulent and hyperepidemic
strain NAP1/B1/027 resulting in severe outbreaks and
causing nosocomial infectious diarrhea [4–7]. The
European C. difficile infection study (ECDIS) findings
show that one in 10 cases of C. difficile infection is
either transferred to intensive care unit, or necessi-
tates colectomy, or dies [2]. Several antimicrobial
treatment including metronidazole and vancomycin
are approved for clinical use and are still recom-
mended by many studies as the treatment of choice
for serious infections [1]. Recently, with the recur-
rence and failure of classical treatments, new thera-
peutic strategies became available such as the novel
US Food and Drug Administration (FDA) approved
antimicrobial agent fidaxomicin, immunoglobulins and
toxin chelators (e.g., cholestyramine, colestipol, toleva-
mer) along with a reevaluation of the conventional
treatments with new recommendations for their use
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[5]. Another reported optional treatment for severe C.
difficile is FMT, which constitutes restoration of the
microbial flora in the lower gastrointestinal tract
through the instilment of feces from healthy donors
[8–10]. Although there is supporting evidence from
different studies proving successful symptomatic reso-
lution within 24 h of the procedure, the infectious
diseases society of America (IDSA) and the European
society of clinical microbiology and infectious diseases
(ESCMID) guidelines concerning FMT recommends
that it should be considered only when there is recurrence
and failure of antibiotic therapy [3, 11, 12]. Few studies in-
dicate a potential therapeutic role for FMT in extra-
intestinal disorders correlated with gut microbiota, such
as cardiovascular disease, multiple sclerosis, colorectal
cancer and others [13, 14]. Our manuscript describes a
FMT case, performed against severe C. difficile infection
for an open heart surgery patient who underwent left ven-
tricular assist device implantation (LVAD). This is the first
case report from Lebanon and the region presenting such
technique. Altogether, FMT holds promise for reducing
antibiotic use and expanding its clinical indications [13].
Case presentation
December 2014, a 65-year-old Lebanese male patient
known to have severe ischemic cardiomyopathy with left
ventricular dysfunction, type II diabetes, hypertension,
and chronic moderate renal impairment, was transferred
to our cardiac surveillance unit at the Beirut Cardiac
Institute (BCI) medical center of Al Rassoul Al Aazam
Hospital (RAH) for heart failure management. This ter-
tiary health care center is a community based hospital,
located in south Beirut in Lebanon and comprised of 2
community medical centers with a total of 260 beds.
Three months prior to his current admission, the
patient had been diagnosed of single vessel coronary dis-
ease, which was managed in a peripheral hospital by an
angioplasty with drug eluting stent implantation to the
left anterior descending artery (LAD). He was then
rehospitalized 2 weeks prior to his transfer to our center,
in the same peripheral hospital, for acute myocardial
infarction and cardiogenic shock. Urgent coronary
angiogram showed occlusion of the LAD stent, the other
arteries were unremarkable. Thus the patient underwent
stent desobstruction, but despite such management his
hemodynamics and left ventricular function did not im-
prove, with failure to wean from inotropes. He was then
referred to our center.
Upon his admission, the clinical exam revealed
hypotension (mean arterial pressure: 65 mmHg), sinus
tachycardia (90/min), cold extremities, pulmonary
crackles, and hepatomegaly (19.3 cm). Electrocardio-
gram showed diffuse Q waves and T waves inversion
in anterior leads; troponin level was high (1.13 ng/ml;
normal range: 0-0.014) and blood test showed ele-
vated creatinine (1.45 mg/dl; normal range: 0.6-1.3).
Cardiac ultrasound showed a dilated left ventricle
with extensive antero septo apical akinesia and a very
low left ventricle ejection fraction (LVEF: 15 %).
Chest X-ray showed subacute pulmonary oedema. We
maintained the inotropes (Dobutamine), and we
inserted an Intra Aortic balloon pump (IABP) on his
second day of admission, allowing stabilization of
hemodynamics and improvement of diuresis and renal
function. Due to the failure of IABP weaning we
performed a HeartWare left ventricular assist device
(HeartWare, USA) on day 12. Intravenous (IV) vanco-
mycin therapy was started empirically three days pre-
operatively (pre-op) and continued post-operatively
(post-op) along with imipenem/cilastatin (IV) as in-
fection prophylaxis. The patient was stable initially,
with no surgery related complications. On day 4 post-
op he developed worsening of his kidney function
with creatinine level reaching 2.37 (mg/dl). Vanco-
mycin therapy was stopped. By day 12 post-op cre-
atinine level decreased (1.46 mg/dl). Nevertheless, the
patient had high white blood cells count (30.3 k/μL;
normal range: 4-11) (Fig. 1); based on empirical evi-
dence Acinetobacter baumannii was suspected and he
was managed with teicoplanin, anidulafungin and
polymyxin E along with imipenem/cilastatin.
By day 14 post-op he developed diarrhea and rector-
rhagia (rectal bleeding) and laboratory testing indicated
negative results for C. difficile antigen. Abdomen and
pelvis Computed tomography (CT) scan showed signifi-
cant thickening of the whole colon and rectum with
surrounding fat stranding, illustrating pancolitis which is
usually unresponsive to medication and requires fre-
quently surgery [15]. Oral vancomycin and metronida-
zole (500 mg PO QID) were administered and former
medicines were sustained. Day 17 post-op, his WBC
decreased but diarrhea persisted, C. difficile antigen
remained negative; culture stool was negative for Sal-
monella and Shigella; Entamoeba histolytica cysts (not

















Fig. 1 White blood cells count (WBC) following LVAD open-heart
surgery in a patient with severe pseumembranous colitis
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being the cause behind colitis) were seen in stool and
occult blood was positive. He was continued on vanco-
mycin and metronidazole, and started on oral rifaximin,
ceftriaxone and probiotics (Euflora). Colonoscopy, per-
formed on day 27 post-op, revealed diffuse colitis, scat-
tered yellowish plaques and large amount of blood
throughout the colon. A biopsy from the left colon was
taken for histological diagnosis and reported benign co-
lonic mucosa with marked thick layer of acute and
chronic inflammatory cells that was most consistent
with severe pseumembranous colitis. The patient was
thus put on cholestyramine (Quantalan and Questran)
regimen. The patient’s condition worsened not respond-
ing to any of the conventional therapy. The gastroenter-
ologist prescribed FMT prior to Protocolectomy. On day
32 post-op, FMT (240 cc) was delivered, following the
local hospital protocol into the duodenum through gas-
troscopy; an unrelated healthy person was the donor
after proper stool testing for common pathogens. The
patient’s diarrhea improved within few hours and clinical
resolution occurred after 24 h.
Conclusions
We describe a case of severe C. difficile-associated diar-
rhea in an advanced heart failure patient who underwent
LVAD surgery at our institution and was successfully
treated with FMT, a technique used for the eradication of
C. difficile-diarrhea, which gained much attention recently
and proved to be more successful than other conventional
treatments. To the best of our knowledge, this is the first
local and regional description for FMTas being therapeut-
ically efficient in hospitalized patients. Fecal microbiota
transplantation was first described in 1958 for the treat-
ment of pseudomembranous colitis [16], it consists pri-
marily of restoring the normal intestinal flora. Several
published cases from USA [17–19], Canada [20], United
kingdom [21], China [22–24], Korea [25], Germany [26],
Switzerland [27], Hungary [28], Italy [29], Denmark [30],
Sweden [31], Norway [32], Romania [33], Finland [34],
Australia [9, 35] and Czech Republic [36] have described
performing FMT and getting good clinical outcomes. Case
reports from France are very rare; in a review article,
French authors explain that since there is no standardized
procedure for FMT, the matter of considering it strictly in
investigational clinical setting must be raised despite its
increasing medical interest [37].
Unfortunately, there are minimal studies from the
Middle Eastern countries informing about the incidence
or the microbiological characteristics of C. difficile
strains [2]. To date, there have been no reports from the
same region describing or recommending the use of
FMT as a treatment for severe C. difficile infection, in-
stead conventional therapies are employed and surgical
procedures are used as a last resort.
Published article, from a Lebanese university hospital,
recommended probiotics as prophylactic agents against
antibiotics-associated diarrhea [38]. El-Herte et al. from
Lebanon reported a case of metronidazole and vanco-
mycin resistant C. difficile treated by a combination of
rifamixin and tigecycline after the refusal of the patient
to undergo surgical procedure [1]. Conversely caution
with the use of tigecycline was urged in a Greek case
report after its failure to treat a severe Clostridium infec-
tion in Intensive care unit (ICU) setting [39]. We point
out here, that our patient didn’t receive tigecycline due
to shortage from medical suppliers during his illness
period. A case study from Turkey treated successfully a
patient, with end-stage renal disease, having C. difficile-
associated diarrhea with metronidazole regimen for ten
days; justifying their findings about the culture-negative
peritonitis by the recent antibiotic therapy, and recom-
mending the consideration of C. difficile in patients with
culture-negative diarrhea [40]. From Iran, Goudarzi et
al. have investigated the susceptibility pattern of C. diffi-
cile clinical isolates and recommended as well metro-
nidazole and vancomycin as first choice drugs for
treatment [41]. Also from Iran Sadeghifard et al. re-
corded susceptibility of C. difficile to chloramphenicol
and ceftriaxone [42]. Jordanian authors detected the
genetic pattern of the C. difficile’s toxins among hospi-
talized patients indicating as well susceptibility towards
metronidazole and vancomycin [43]. Similar susceptibil-
ity studies were done in Kuwait and Saudi Arabia de-
scribing antibiotic resistances without proposing any
potential solutions [44, 45]; just one report by Abdulaziz
et al. informed about the use of intravenous immuno-
globulin as adjuvant to antibiotics ensuing with success-
ful outcome [46]. Hospitals in Quatar as well continue
on using conventional treatments even for severe cases
of C. difficile [47, 48]. Published data from Israel re-
ported and recommended the use of conventional anti-
biotics [49–51] as successful therapy against C. difficile.
However, despite such guidelines from their country, a
recent study from Israel in collaboration with Boston,
USA developed frozen FMT capsules for patients with
recurrent C. difficile infection, and evaluated the safety
and effectiveness of such administration [52]. This might
open a solution for the standardization of the FMT pro-
cedure. We tried to order FMT capsules for our patient,
but there were some restrictions from the suppliers’ side,
since they require from patients willing to try this treat-
ment to be administered and followed directly by USA
providers for investigational purposes.
FMT preparation following the local hospital protocol
successfully resolved our patient’s symptoms without
recourse to surgery. In conclusion, we recommend fecal
microbiota transplantation, for severe forms of C. diffi-
cile infection, as the best option for treatment.
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